DA Davidson upgraded Prestige Consumer to Buy from Neutral with a price target of $93, up from $65. After having met with management, the firm believes the company can make their guidance and that the Clear Eyes supply chain issues are temporary. The firm, which expects free cash flow of about $1B, or one-third of the market cap, in the next four years, is switching its valuation method, driving its price target hike, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- Prestige Consumer management to meet with Oppenheimer
- Prestige Consumer falls -10.8%
- Prestige Consumer Healthcare Announces Buyback, Shares Financials
- Prestige Consumer sees FY25 EPS $4.40-$4.46, consensus $4.62